Kane Biotech Inc V.KNE

New Press Release - Kane Biotech Receives Funding Support to Expand the revyve(TM) Antimicrobial Wound Gel Family

WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $200,000 in research and development funding from the National Research Council of Canada...read article.

[francoisl13]

Nice flow of news since mid-2023, like it. The 'Revyve' line of products is going to be the cornerstone of this company. GLTA

[KevinOleary]

Not likely - hydrogels are presently only a $260M market, and that includes some cheap stuff, so revyve might not get that portion. If Revyve gets all of the hydrogel market and adds some uses it will still be much less than a successful Dispersin.

[francoisl13]

Hello KevinOleary, nice to hear from you! I think that the Revyve line of products will be the cornerstone of this company since it is already FDA approved, the price point seems to be in-line with the market requirements and they are already expanding the offering. The OTC aproval was key to me, it is allowing KNE to search for commercial partners that are involved in the 'consumer goods'

[KevinOleary]

That's all true. Cornerstone for awhile at least.